OCX - OncoCyte Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
1.70
-0.12 (-6.59%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.82
Open1.70
Bid0.00 x 3000
Ask0.00 x 1000
Day's Range1.69 - 1.85
52 Week Range1.10 - 6.45
Volume18,130
Avg. Volume49,040
Market Cap69.13M
Beta (3Y Monthly)3.43
PE Ratio (TTM)N/A
EPS (TTM)-0.58
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.69
Trade prices are not sourced from all markets
  • Associated Pressyesterday

    OncoCyte: 3Q Earnings Snapshot

    On a per-share basis, the Alameda, California-based company said it had a loss of 7 cents. In the final minutes of trading on Tuesday, the company's shares hit $1.82. A year ago, they were trading at $5.95. ...

  • GlobeNewswireyesterday

    OncoCyte Reports Third Quarter 2018 Financial Results and Progress in DetermaVu™ Development

    Transition to New Diagnostic Testing Platform Complete Prospective R&D Validation Study Results Expected by Late 2018 or Early 2019 Development Plan Remains On-Track,.

  • GlobeNewswire8 days ago

    Oncocyte to Report Third Quarter 2018 Financial Results on November 13, 2018

    OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results for the third quarter ended September 30, 2018, on Tuesday, November 13, 2018, after the close of the U.S. financial markets. The Company will host a conference call on Tuesday, November 13, 2018, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments. For all callers, please refer to Conference ID 13684100.

  • GlobeNewswire16 days ago

    OncoCyte Completes Successful Transition to New Diagnostic Testing Platform and Initiates DetermaVu™ Development Studies

    OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today provided an update on its successful transition to a new diagnostic testing platform and initiation of a series of studies designed to make its DetermaVu™ lung cancer assay available for the medical market in the second half of 2019. OncoCyte has completed its transition to an industry standard Next Generation Sequencing (NGS) diagnostic testing platform, including installation, training and operational qualification. Based on these positive results, OncoCyte has initiated the 700-blood sample Algorithm Development Study to establish a proprietary mathematical algorithm that will be used to interpret test results for DetermaVu™.

  • See what the IHS Markit Score report has to say about OncoCyte Corp.
    Markit27 days ago

    See what the IHS Markit Score report has to say about OncoCyte Corp.

    Short interest is low for OCX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding OCX is favorable, with net inflows of $2.50 billion.

  • GlobeNewswire28 days ago

    OncoCyte Corporation to Present at the BIO CEO Investor Forum

    ALAMEDA, Calif., Oct. 17, 2018 -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that.

  • See what the IHS Markit Score report has to say about OncoCyte Corp.
    Markitlast month

    See what the IHS Markit Score report has to say about OncoCyte Corp.

    Short interest is low for OCX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding OCX is favorable, with net inflows of $4.08 billion.

  • See what the IHS Markit Score report has to say about OncoCyte Corp.
    Markit2 months ago

    See what the IHS Markit Score report has to say about OncoCyte Corp.

    Short interest is low for OCX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding OCX is favorable, with net inflows of $2.22 billion.

  • See what the IHS Markit Score report has to say about OncoCyte Corp.
    Markit2 months ago

    See what the IHS Markit Score report has to say about OncoCyte Corp.

    Short interest is low for OCX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding OCX totaled $207 million.

  • See what the IHS Markit Score report has to say about OncoCyte Corp.
    Markit3 months ago

    See what the IHS Markit Score report has to say about OncoCyte Corp.

    Short interest is low for OCX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold OCX had net inflows of $687 million over the last one-month.

  • Associated Press3 months ago

    OncoCyte: 2Q Earnings Snapshot

    On a per-share basis, the Alameda, California-based company said it had a loss of 12 cents. In the final minutes of trading on Tuesday, the company's shares hit $2.85. A year ago, they were trading at ...

  • Who Are The Major Shareholders In OncoCyte Corporation (NYSEMKT:OCX)?
    Simply Wall St.3 months ago

    Who Are The Major Shareholders In OncoCyte Corporation (NYSEMKT:OCX)?

    In this article, I will take a quick look at OncoCyte Corporation’s (NYSEMKT:OCX) recent ownership structure – an unconventional investing subject, but an important one. A company’s ownership structure isRead More...

  • See what the IHS Markit Score report has to say about OncoCyte Corp.
    Markit4 months ago

    See what the IHS Markit Score report has to say about OncoCyte Corp.

    Short interest is low for OCX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding OCX totaled $877 million.

  • OncoCyte (OCX) in Focus: Stock Moves 13.1% Higher
    Zacks4 months ago

    OncoCyte (OCX) in Focus: Stock Moves 13.1% Higher

    OncoCyte (OCX) was a big mover last session, as the company saw its shares rise more than 13% on the day.

  • ACCESSWIRE4 months ago

    Today's Research Reports on Stocks to Watch: Loxo Oncology and OnoCyte

    NEW YORK, NY / ACCESSWIRE / July 11, 2018 / Shares of Loxo Oncology were in the red on Tuesday almost 6% despite any news. Shares of OncoCyte were gaining full speed after announcing that the DetermaVu diagnostic test for lung cancer saw better performance than the company was expecting. Loxo Oncology, Inc. shares closed down almost 6% on Tuesday with around 1 million shares traded.

  • InvestorPlace4 months ago

    OncoCyte (OCX) Stock Skyrockets on Lung Cancer Test Study Results

    The California-based company announced that its DetermaVu diagnostic test for lung cancer churned out a better performance than the company was expecting. OncoCyte’s impressive results have encouraged the company to move DetermaVu to a different and better testing platform that would help “resolve the inconsistent data issues” that plagued the company in previous versions of the biopsy test, according to its press release. The company had to previously delay the test’s clinical validation study that launched in November 2017 as test results came back as irregular due to a “variance in the lots of consumables” of the blood sample-testing system, according to OncoCyte’s 2017 annual earnings report.

  • TheStreet.com4 months ago

    OncoCyte Surges on 'Encouraging' Results for Diagnostic Test for Cancer

    soared by more than 40% after the company released "encouraging" test results for its lung cancer blood diagnostic test. Shares rose $1.33 -- or 43.25% -- to $4.41 in early trading Tuesday after OncoCyte announced that its DetermaVu diagnostic test for lung cancer performed better than the company expected it would. The results of the study justify moving DetermaVu to a different and better testing platform that would "resolve the inconsistent data issues" OncoCyte dealt with in previous versions of the biopsy test, according to the release.

  • Benzinga4 months ago

    Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 9) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Arrowhead Pharmaceuticals ...

  • OncoCyte Sees Hammer Chart Pattern: Time to Buy?
    Zacks4 months ago

    OncoCyte Sees Hammer Chart Pattern: Time to Buy?

    OncoCyte Sees Hammer Chart Pattern: Time to Buy?